BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Alzheimer's disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for Alzheimer disease: 215 (144 sponsors; 48 newly posted in the last 180 days, 8 stopped in the last 180 days; 27 new-entrant sponsors). Momentum score 21.2, rank 25 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 42, Phase 2 55, Phase 3 53, Phase 4 7, N/A 56.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Eli Lilly and Company LLY | 20 | P4 1, P3 8, NA 4, P1 6, P2 1 | 5 | 0 |
| Bristol-Myers Squibb BMY | 8 | P3 6, P1 1, P2 1 | 1 | 1 |
| Hoffmann-La Roche | 8 | P3 4, P2 3, P1 1 | 2 | 2 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 4 | P3 4 | 0 | 2 |
| Eisai Inc. | 7 | P3 2, P2 1, NA 3, P1 1 | 4 | 2 |
| Eidos Therapeutics, a BridgeBio company | 3 | P4 1, P3 2 | 1 | 0 |
| ACADIA Pharmaceuticals Inc. ACAD | 2 | P3 2 | 0 | 0 |
| Annovis Bio Inc. ANVS | 2 | P3 2 | 1 | 0 |
| JYAMS PET Research & Development Limited | 2 | P3 2 | 1 | 2 |
| AB Science | 1 | P3 1 | 0 | 0 |
| Actinogen Medical | 1 | P3 1 | 0 | 0 |
| AriBio Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Benuvia Therapeutics Inc. | 1 | P3 1 | 0 | 0 |
| Bigespas LTD | 1 | P3 1 | 0 | 1 |
| Cerecin | 1 | P3 1 | 0 | 0 |
| CereMark Pharma, LLC | 1 | P3 1 | 0 | 0 |
| Danyang Huichuang Medical Equipment Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Exciva GmbH | 1 | P3 1 | 0 | 0 |
| HTA Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Incyte Corporation INCY | 1 | P3 1 | 0 | 0 |
| Lantheus Biosciences Ltd. LNTH | 1 | P3 1 | 0 | 0 |
| Moleac Pte Ltd. | 1 | P3 1 | 0 | 0 |
| Samsung Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| ScandiBio Therapeutics AB | 1 | P3 1 | 0 | 0 |
| Sichuan Jishengtang Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
New-entrant sponsors: HTA Co., Ltd..
Recently stopped trials
- NCT06993207 Bitbrain - terminated: Due to time and funding constraints, recruitment for the cross-over phase closed before enrolling the planned 500 participants, and the long HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population
- NCT04619420 Janssen Research & Development, LLC - terminated: Posdinemab did not achieve statistical significance in slowing clinical decline A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
- NCT03536767 Eidos Therapeutics, a BridgeBio company - terminated: Study ended by the sponsor due to meeting Study Objectives Open-Label Study of AG10 in Patients With Cardiomyopathy
- NCT06079190 GlaxoSmithKline - terminated: The study was terminated early due to meeting pre-specified efficacy futility criteria at planned interim analysis. Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
- NCT05267535 Neurim Pharmaceuticals Ltd. - terminated: Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale a Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
- NCT06721156 Merck Sharp & Dohme LLC - terminated: Termination Notes: Business reason A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
- NCT06736509 Axsome Therapeutics, Inc. - terminated: Study AXS-05-AD-305 was terminated due to completion of overall program objectives. An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-
- NCT06304883 Alzheon Inc. - terminated: Sponsor business decision Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-19 est. | P2 | Hoffmann-La Roche | NCT06402838 A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | Alzheimer's Disease | active not recruiting | 256 |
| 2026-11-24 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer Disease | recruiting | 406 |
| 2026-12 est. | P3 | Suven Life Sciences Limited | NCT05397639 Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Agitation; Alzheimer's Type Dementia | active not recruiting | 375 |
| 2026-12-01 est. | P3 | JYAMS PET Research & Development Limited | NCT07422857 Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function | Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia | recruiting | 316 |
| 2026-12-03 est. | P2 | Eisai Inc. | NCT06602258 A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | Alzheimer's Disease | active not recruiting | 105 |
| 2026-12-09 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT06126224 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Psychosis Associated With Alzheimer's Disease | recruiting | 500 |
| 2026-12-17 est. | P2 | Bristol-Myers Squibb BMY | NCT06268886 Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | Alzheimer Disease, Early Onset | active not recruiting | 310 |
| 2026-12-22 est. | P2 | Janssen Pharmaceutica N.V., Belgium | NCT06544616 A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Alzheimer Disease | active not recruiting | 55 |
| 2026-12-31 est. | P3 | Eisai Inc. | NCT03887455 A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Early Alzheimer's Disease | active not recruiting | 1906 |
| 2026-12-31 est. | P2 | Excelsior | NCT05413655 A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease | Alzheimer Disease | recruiting | 120 |
| 2026-12-31 est. | P2 | Ono Pharmaceutical Co., Ltd. | NCT06803823 A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia | Agitation Associated With Alzheimer's Disease Dementia | recruiting | 90 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-05-01 | PDUFA date (company-disclosed) | pending | Axsome Therapeutics, Inc. AXSM | PDUFA May 1, 2027 - Axsome Therapeutics, Inc. |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | IGC Pharma, LLC IGC | NCT05543681 Clinical Trial on Agitation in Alzheimer's Dementia | Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden; NPS; Aggression | active not recruiting | 164 |
| 2026-10-29 | P2 | Acumen Pharmaceuticals ABOS | NCT06335173 A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) | Alzheimer Disease | active not recruiting | 542 |
| 2026-10-13 | P1/P2 | Voyager Therapeutics VYGR | NCT06874621 VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease | Alzheimer's Disease (AD) | active not recruiting | 52 |
| 2026-10-05 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT05511363 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Psychosis Associated With Alzheimer's Disease | recruiting | 410 |
| 2026-09-22 | P2/P3 | Actinogen Medical | NCT06125951 Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | Dementia Moderate; Dementia, Mild; Alzheimer Disease | active not recruiting | 247 |
| 2026-09 est. | P3 | ScandiBio Therapeutics AB | NCT07062198 Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease | Alzheimer Disease | recruiting | 845 |
| 2026-08-31 est. | P3 | Sichuan Jishengtang Pharmaceutical Co., Ltd. | NCT06534723 Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney) | Alzheimer's Dementia | recruiting | 570 |
| 2026-07-31 | P2 | Ono Pharmaceutical Co., Ltd. | NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | Alzheimer Disease | completed | 260 |
| 2026-07-30 est. | P1/P2 | NSC-Therapeutics | NCT06995573 A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease | Alzheimer Disease | recruiting | 90 |
| 2026-06-29 | P3 | AriBio Co., Ltd. | NCT05531526 Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polari | Alzheimer Disease | active not recruiting | 1535 |
| 2026-06-05 | P2 | Merck Sharp & Dohme LLC MRK | NCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Alzheimer Disease; Dementia | terminated | 369 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Alzheimer disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.